Genes and patent policy: rethinking intellectual property rights

  title={Genes and patent policy: rethinking intellectual property rights},
  author={Lori B. Andrews},
  journal={Nature Reviews Genetics},
  • L. Andrews
  • Published 1 October 2002
  • Political Science
  • Nature Reviews Genetics
Concerns about human gene patents go beyond moral disquiet about creating a commodity from a part of the human body and also beyond legal questions about whether genes are unpatentable products of nature. New concerns are being raised about harm to public health and to research. In response to these concerns, various policy options, such as litigation, legislation, patent pools and compulsory licensing, are being explored to ensure that gene patents do not impede the practice of medicine and… 
Patents on Human Genes: An Analysis of Scope and Claims
The authors of this Policy Forum describe their study, which examined issued gene patents covering a variety of genetic diseases and described ways in which many claims fell short of USPTO patentability requirements.
Gene Patents: A Brief Overview of Intellectual Property Issues
This report is a brief discussion of the ethical, legal, and economic issues of gene patenting. The courts have upheld gene patents that meet the criteria of patentability defined by the Patent Act.
Intellectual Property Landscape of the Human Genome
The impact of gene patents on downstream research and innovation are unknown, in part because of a lack of empirical data on the extent and nature of gene patenting. In this Policy Forum, the
The BRCA Gene Patents: Arguments Over Patentability and Social Utility
Beginning in 2011, a series of contradictory U.S. court decisions cast doubt on the patentability of Myriad Genetics' BRCA1 and BRCA2, the primary genes responsible for breast and ovarian cancer.
Is there a future for 'speculative' gene patents in Europe?
The recent state of the law in Europe as it applies to gene patents is reviewed in order to determine whether there is any hope for the modern heirs of Galilean innovation.
Gene patenting and medical research: a view from a pharmaceutical company
This article seeks to evaluate the impact of gene patenting objectively by examining, in overall terms, whether there has been a net cost or benefit to medical research from gene patents.
Decoding the research exemption
This work believes that gene patents raise several unique issues that are inadequately handled by the current research exemptions, and there is no international consensus about the extent of required protections.
It’s About Scientific Secrecy, Dummy: A Better Equilibrium Among Genomics Patenting, Scientific Research and Health Care
It is argued that the uniqueness of PPPAs lies in subsequently mitigating the negative ramifications of genetic patents on scientific research and genetic-based health care services, while basing such mitigation on a patents’ advocate viewpoint that neither discards the patent system nor jeopardizes its integrity.
University-based science and biotechnology products: defining the boundaries of intellectual property.
The pharmaceutical and biotechnology industries have long relied on patenting as the primary means of allocating ownership and control over new discoveries. Yet, patent protection is a double-edged


Patenting human genetic material: refocusing the debate
Concerns over the patentability of human genetic material are discussed, the patent authorities' response to them, and ways in which to address these issues and to move the debate forward using current legal structures are discussed.
Can Patents Deter Innovation? The Anticommons in Biomedical Research
Privatization of biomedical research must be more carefully deployed to sustain both upstream research and downstream product development, because more intellectual property rights may lead paradoxically to fewer useful products for improving human health.
International conflicts over patenting human DNA sequences in the United States and the European Union: an argument for compulsory licensing and a fair-use exemption.
The thought of a large biotech company holding an exclusive right to research and manipulate human genetic material provokes many reactions--from moral revulsion to enthusiasm about the possibilities
The Patenting of DNA
The U.S. Patent and Trademark Office presents its view that, as in other fields of technology, DNA-related inventions may be patentable if they meet all the conditions for patentability, including, for example, utility, novelty, nonobviousness, written description and enablement.
Whose DNA Is It, Anyway?
A patients rights organization has taken matters into its own hands by sponsoring research projects with the proviso that data be shared, and at stake are the rights of donors to research results derived from their own DNA.
Religion and Gene Patenting
The author responds to a statement opposing the patenting of life issued by religious leaders by arguing that religious bodies have historically been supportive of science and that new channels of communication are opening between the two communities.
Future Perfect: Confronting Decisions About Genetics
This chapter discusses the changing face of Parenthood in the Genetics Era, the impact of Genetic Services on Women, People of Color, and Individuals with Disabilities, and competing Frameworks for Genetics Policy.
Innovation policy and the economy
The economic importance of innovative activity brings with it an active debate on the effect of public policy on the innovation process. This annual series, sponsored by the National Bureau of
Owning the Future:
  • S. Shulman
  • Economics
    Occidentalism, Conspiracy and Taboo
  • 2019
From the Publisher: Knowledge is the key variable of the new global economy. But in the rush to stake claims in the knowledge economy, players are losing sight of impending threats to innovation,